AR043507A1 - Derivados de anilina sustituidos y composiciones farmaceuticas - Google Patents
Derivados de anilina sustituidos y composiciones farmaceuticasInfo
- Publication number
- AR043507A1 AR043507A1 ARP040100733A ARP040100733A AR043507A1 AR 043507 A1 AR043507 A1 AR 043507A1 AR P040100733 A ARP040100733 A AR P040100733A AR P040100733 A ARP040100733 A AR P040100733A AR 043507 A1 AR043507 A1 AR 043507A1
- Authority
- AR
- Argentina
- Prior art keywords
- cycloalkyl
- ilo
- alkyl
- amino
- phenyl
- Prior art date
Links
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical class NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Chemical class 0.000 title 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 17
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 8
- 125000002252 acyl group Chemical group 0.000 abstract 6
- 125000005350 hydroxycycloalkyl group Chemical group 0.000 abstract 5
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 125000001188 haloalkyl group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 2
- 125000002490 anilino group Chemical class [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 125000005347 halocycloalkyl group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- AQIYYEYDCKZSCQ-UHFFFAOYSA-N n-[4-[[(2,4-diaminoquinazolin-6-yl)amino]methyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1CNC1=CC=C(N=C(N)N=C2N)C2=C1 AQIYYEYDCKZSCQ-UHFFFAOYSA-N 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- -1 1H-imidazol-1-ylmethyl Chemical group 0.000 abstract 1
- 102000004257 Potassium Channel Human genes 0.000 abstract 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 abstract 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- JTNKTTCJVFXBEH-UHFFFAOYSA-N n-[4-[(3,4,5-trimethoxyanilino)methyl]phenyl]acetamide Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C=CC(NC(C)=O)=CC=2)=C1 JTNKTTCJVFXBEH-UHFFFAOYSA-N 0.000 abstract 1
- QOUWPCGZCSHNRK-UHFFFAOYSA-N n-[4-[(4-amino-2-methylanilino)methyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1CNC1=CC=C(N)C=C1C QOUWPCGZCSHNRK-UHFFFAOYSA-N 0.000 abstract 1
- GLIFJWDTFOEGAR-UHFFFAOYSA-N n-[4-[(4-amino-3,5-dichloroanilino)methyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1CNC1=CC(Cl)=C(N)C(Cl)=C1 GLIFJWDTFOEGAR-UHFFFAOYSA-N 0.000 abstract 1
- VOOCWXWSNXHKBV-UHFFFAOYSA-N n-[4-[(4-amino-3-methylanilino)methyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1CNC1=CC=C(N)C(C)=C1 VOOCWXWSNXHKBV-UHFFFAOYSA-N 0.000 abstract 1
- IUICPWUFTFHFNJ-UHFFFAOYSA-N n-[4-[(4-aminoanilino)methyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1CNC1=CC=C(N)C=C1 IUICPWUFTFHFNJ-UHFFFAOYSA-N 0.000 abstract 1
- BDFMGMYOZMUMDN-UHFFFAOYSA-N n-[4-[[(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)amino]methyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1CNC1=CC=C2C(C)(C)CCC(C)(C)C2=C1 BDFMGMYOZMUMDN-UHFFFAOYSA-N 0.000 abstract 1
- PFUWYMNNTQXYIU-UHFFFAOYSA-N n-[4-[[2-(imidazol-1-ylmethyl)anilino]methyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1CNC1=CC=CC=C1CN1C=NC=C1 PFUWYMNNTQXYIU-UHFFFAOYSA-N 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 108020001213 potassium channel Proteins 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente se refiere a derivados de anilina sustituidos. Los compuestos son útiles para la prevención, tratamiento e inhibición de trastornos y enfermedades sensibles a la apertura de los canales iónicos de potasio de la fórmula KCNQ, siendo una de tales enfermedades la epilepsia. Reivindicación 1: Un derivado de anilina sustituida de fórmula (1) en la cual U es O, S o NR2´; s es 0 o 1; X es CO o SO2;Z es O, S o NR4, donde R4 se selecciona del grupo formado por H, alqu(en(in)ilo C1-6, cicloalqu(en)ilo C3-8, cicloalqu(en)il C3-8-alqu(en(in)ilo C1-6, hidroxi-alqu(en/in)ilo C1-6 e hidroxi-cicloalqu(en)ilo C3-8; q es 0 o 1; R1 y R1´ se seleccionan independientemente del grupo formado por H, alqu(en(in)ilo C1-6, cicloalqu(en)ilo C3-8, cicloalqu(en)ilo C3-8-alqu(en(in)ilo C1-6, acilo, hidroxi-alqu(en(in)ilo C1-6, hidroxi-cicloalqu(en)ilo C3-8, halo-alqu(en/in)ilo C1-6 y halo-cicloalqu(en)ilo C3-8-; R2 se selecciona del grupo formado por hidrógeno, halógeno, alqu(en(in)ilo C1-6, cicloalqu(en)ilo C3-8, cicloalqu(en)il C3-8-alqu(en(in)ilo C1-6, Ar, Ar-alqu(en(in)ilo C1-6, Ar-cicloalqu(en)ilo C3-8, acilo, hidroxi-alqu(en(in)ilo C1-6,hidroxi-cicloalqu(en)ilo C3-8, halo-alqu(en(in)ilo C1-6, halo-cicloalqu(en)ilo C3-8 y ciano; siempre que cuando R2 sea halógeno o ciano, entonces s sea 0; cuando s es 1 y U es NR2´ entonces R2´ se selecciona del grupo formado por H, alqu(en(in)ilo C1-6, cicloalqu(en)ilo C3-8, cicloalqu(en)il C3-8-alqu(en(in)ilo C1-6, Ar, Ar-alqu(en(in)ilo C1-6, Ar-cicloalqu(en)ilo C3-8, acilo, hidroxi-alqu(en(in)ilo C1-6,hidroxi-cicloalqu(en)ilo C3-8, halo-alqu(en(in)ilo C1-6, halo-cicloalqu(en)ilo C3-8 ; o R2 y R2´ juntos forman un anillo saturado o insaturado de 5-8 miembros que contiene opcionalmente otro heteroátomo; R3 se selecciona del grupo formado por alqu(en(in)ilo C1-6, cicloalqu(en)ilo C3-8, cicloalqu(en)il C3-8-alqu(en(in)ilo C1-6, Ar, Ar-alqu(en(in)ilo C1-6, Ar-cicloalqu(en)ilo C3-8, acilo, hidroxi-alqu(en(in)ilo C1-6,hidroxi-cicloalqu(en)ilo C3-8, halo-alqu(en(in)ilo C1-6, y halo-cicloalqu(en)ilo C3-8; e Y representa un grupo de fórmula (6), (7), (8), (9) o (30): en las cuales la línea representa un enlace que une el grupo representado por Y al átomo de N; W es O o S; a es 0, 1, 2 o 3; b es 0, 1,2,3 o 4; c es 0 o 1; d es 0, 1, 2, o 3; e es 0, 1 o 2; f es 0, 1, 2, 3, 4 o 5; g es 0, 1, 2, 3 o 4; h es 0, 1, 2, o 3; y cada R5 se selecciona independientemente del grupo formado por alqu(en(in)ilo C1-6, cicloalqu(en)ilo C3-8, Ar, cicloalqu(en)ilo C3-8-alqu(en(in)ilo C1-6, Ar-alqu(en(in)ilo C1-6, acilo, alqu(an/en/in)iloxi C1-6, halógeno, halo-alqu(en(in)ilo C1-6, -CO-NR6R6´, ciano, nitro, -NR76R7´, -S-R8, -SO2R8 y SO2OR8, o dos sustituyentes juntos forman un anillo saturado o insaturado de 5-8 miembros que contiene opcionalmente uno o dos heteroátomos; R6 y R6´ se seleccionan independientemente del grupo formado por H, alqu(en(in)ilo C1-6, cicloalqu(en)ilo C3-8, cicloalqu(en)il C3-8-alqu(en(in)ilo C1-6 y Ar; R7 y R7´ se seleccionan independientemente del grupo formado por H, alqu(en(in)ilo C1-6, cicloalqu(en)ilo C3-8, cicloalqu(en)il C3-8-alqu(en(in)ilo C1-6, Ar y acilo; y R8 se selecciona del grupo formado por H, alqu(en(in)ilo C1-6, cicloalqu(en)ilo C3-8, cicloalqu(en)il C3-8-alqu(en(in)ilo C1-6, Ar y -NR9R9´; donde R9 y R9´ se seleccionan independientemente del grupo formado por H, alqu(en(in)ilo C1-6, cicloalqu(en)ilo C3-8, cicloalqu(en)il C3-8-alqu(en(in)ilo C1-6; con las salvedades que cuando R5 es SO2OR8 entonces R8 no es -NR9R9´ y cuando R5 es SO2R8, entonces R8 no es un átomo de H; o sus sales; con la salvedad de que el compuesto de fórmula (1) no sea: N-[4-[[(4-aminofenil)amino]metil]fenil]-acetamida; N-[4-[[(4-amino-2-metilfenil)amino]metil]fenil]-acetamida; N-[4-[[(4-amino-3-metilfenil)amino]metil]fenil]-acetamida; 2-[[[4-(acetilamino)fenil]metil]amino[-5-cloro-N-(5-cloro-2-piridinil)-benzamida; N-[4-[[(3,4,5-trimetoxifenil)amino]metil]fenil]-acetamida; N-[4-[[(5,6,7,8-tetrahidro-5,5,8,8-tetrametil-2-naftalenil)amino]metil]fenil]-acetamida; N-[4-[[[(3-(1H-imidazol-1-ilmetil)fenil]amino]metil]fenil]-acetamida; N-[4-[[[(2-(1H-imidazol-1-ilmetil)fenil]amino]metil]fenil]-acetamida; N-[4-[[(4- amino-3,5-diclorofenil)amino]metil]fenil]-acetamida; N-[4-[[(2,4-diamino-6-quinazolinil)amino]metil]fenil]-acetamida; o N-[4-[[(2,4-diamino-6-quinazolinil)amino]metil]fenil]-acetamida.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200300392 | 2003-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR043507A1 true AR043507A1 (es) | 2005-08-03 |
Family
ID=58707220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040100733A AR043507A1 (es) | 2003-03-14 | 2004-03-08 | Derivados de anilina sustituidos y composiciones farmaceuticas |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20060167087A1 (es) |
| KR (1) | KR20050117563A (es) |
| CN (1) | CN1759099A (es) |
| AR (1) | AR043507A1 (es) |
| CL (1) | CL2004000488A1 (es) |
| EA (1) | EA200501299A1 (es) |
| IS (1) | IS7924A (es) |
| NO (1) | NO20054721L (es) |
| NZ (1) | NZ541242A (es) |
| SG (1) | SG171472A1 (es) |
| UA (1) | UA81799C2 (es) |
| ZA (1) | ZA200505357B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7799832B2 (en) * | 2003-10-23 | 2010-09-21 | Valeant Pharmaceuticals North America | Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains |
| US8722929B2 (en) * | 2006-10-10 | 2014-05-13 | Valeant Pharmaceuticals International | N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators |
| US8563566B2 (en) * | 2007-08-01 | 2013-10-22 | Valeant Pharmaceuticals International | Naphthyridine derivatives as potassium channel modulators |
| US7786146B2 (en) * | 2007-08-13 | 2010-08-31 | Valeant Pharmaceuticals International | Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators |
| AU2009271302A1 (en) * | 2008-06-24 | 2010-01-21 | Valeant Pharmaceuticals International | Benzyloxy anilide derivatives useful as potassium channel modulators |
| WO2011144761A1 (en) | 2010-05-21 | 2011-11-24 | Universität Für Bodenkultur Wien | Compositions for use in treating or diagnosing bone disorders and/or cardiovascular disorders |
| US20130210883A1 (en) | 2010-05-21 | 2013-08-15 | Johannes Grillari | Lipase inhibitors |
| EP2948433B1 (en) * | 2013-01-22 | 2017-04-26 | Technische Universität Graz | Atglistatin as lipase inhibitor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3903989A1 (de) * | 1989-02-10 | 1990-09-20 | Basf Ag | Diphenylheteroalkylderivate, ihre herstellung und daraus hergestellte arzneimittel und kosmetika |
| CA2076012A1 (en) * | 1990-02-14 | 1991-08-15 | Yasuyuki Kato | Agent for inhibiting the formation of denatured ldl |
| US6472165B1 (en) * | 1999-08-03 | 2002-10-29 | Arzneimittelwerk Dresden Gmbh | Modulatory binding site in potassium channels for screening and finding new active ingredients |
| EP1369420A1 (en) * | 2002-06-06 | 2003-12-10 | Aventis Pharma Deutschland GmbH | Inhibitors of the GPib - vWF interaction |
-
2004
- 2004-03-08 AR ARP040100733A patent/AR043507A1/es not_active Application Discontinuation
- 2004-03-10 CL CL200400488A patent/CL2004000488A1/es unknown
- 2004-03-12 US US10/549,345 patent/US20060167087A1/en not_active Abandoned
- 2004-03-12 KR KR1020057017223A patent/KR20050117563A/ko not_active Ceased
- 2004-03-12 SG SG200718941-8A patent/SG171472A1/en unknown
- 2004-03-12 NZ NZ541242A patent/NZ541242A/en unknown
- 2004-03-12 EA EA200501299A patent/EA200501299A1/ru unknown
- 2004-03-12 CN CNA2004800067754A patent/CN1759099A/zh active Pending
- 2004-03-12 ZA ZA200505357A patent/ZA200505357B/en unknown
- 2004-12-03 UA UAA200508717A patent/UA81799C2/uk unknown
-
2005
- 2005-06-30 IS IS7924A patent/IS7924A/is unknown
- 2005-10-13 NO NO20054721A patent/NO20054721L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20060167087A1 (en) | 2006-07-27 |
| UA81799C2 (uk) | 2008-02-11 |
| NZ541242A (en) | 2009-01-31 |
| IS7924A (is) | 2005-06-30 |
| ZA200505357B (en) | 2006-12-27 |
| KR20050117563A (ko) | 2005-12-14 |
| CL2004000488A1 (es) | 2005-01-07 |
| NO20054721L (no) | 2005-10-13 |
| CN1759099A (zh) | 2006-04-12 |
| SG171472A1 (en) | 2011-06-29 |
| EA200501299A1 (ru) | 2006-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202090658A1 (ru) | Ингибиторы кэп-зависимой эндонуклеазы | |
| NO974844D0 (no) | Benzimidazolforbindelser, farmasöytiske sammensetninger som inneholder forbindelsene og deres anvendelser | |
| AR036659A1 (es) | Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos | |
| PE20060693A1 (es) | Nuevos derivados de trifluorometansulfonanilida oxamida eter | |
| PE20211203A1 (es) | Compuestos para el tratamiento de trastornos dependientes de cinasas | |
| AR070513A1 (es) | Uso de abridores de canales de potasio kcnq para reducir los sintomas o tratar desordenes o afecciones en las cuales se encuentra anulado el sis-tema dopaminergico como por ejemplo esquizofrenia y trastorno depresivo mayor | |
| AR038883A1 (es) | Compuestos que modulan la actividad de ppar, composicion farmaceutica que los contiene y un metodo para prepararlos | |
| AR041672A1 (es) | Compuesto biciclico de benzamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimiento para prepararlo | |
| AR066331A1 (es) | Piridonacarboxamidas agentes protectores de plantas utiles que contienen a estas y procedimientos para su preparacion y su utilizacion | |
| AR051403A1 (es) | Derivados de purina, purinona y deazapurina como inhibidores de la actividad de la protein quinasa; metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la elaboracion de un medicamento para el tratamiento de enfermedades mediadas por la protein quinasa a y b. | |
| RU2014145819A (ru) | Бициклическое соединение | |
| AR046792A1 (es) | Fenilalanina-amidas sustituidas por heteroaroilo, un procedimiento para su preparacion, utilizacion de las mismas como herbicidas y productos fitosa-nitarios que los contienen como principio activo | |
| AR038881A1 (es) | Compuestos que modulan la actividad de ppar, composicion farmaceutica que los contiene y un procedimiento para la preparcion de aquellos | |
| NO974843L (no) | Benzimidazolforbindelser, farmasöytiske sammensetninger som inneholder forbindelsene og deres anvendelser | |
| AR040700A1 (es) | Derivados de pirimidilsulfonamida como moduladores de receptores de quimioquinas | |
| AR049110A1 (es) | Compuestos terapeuticos: piridina como andamiaje estructural | |
| AR012181A1 (es) | Un derivado de pirimidina, procedimientos para prepararlo, una composicion farmaceutica que lo comprende, y un compuesto util como intermediario parapreparar dicho derivado de pirimidina. | |
| AR043485A1 (es) | Derivados del 8'-piridinil-dihidrospiro-[cicloalquil]-pirimido[1,2a]pirimidin-6-ona y 8´-pirimidinil-dihidrospiro-[cicloalquil]-pirimido[1,2a]pirimidin-6-ona substituidos | |
| AR043048A1 (es) | Derivados de 4-(3,3-dihalo- aliloxi) fenol con propiedades pesticidas | |
| AR043507A1 (es) | Derivados de anilina sustituidos y composiciones farmaceuticas | |
| PE20221025A1 (es) | Inhibidores de los receptores a2c adrenergicos | |
| CR20240203A (es) | Compuestos de heteroaril-urea novedosos como inhibidores de kv7.2 | |
| AR082534A1 (es) | Compuestos que interactuan con proteina reguladora de glucocinasa para el tratamiento de diabetes | |
| AR041376A1 (es) | Piperazinas sustituidas por heterociclos para el tratamiento de la esquizofrenia | |
| AR046176A1 (es) | Procedimiento para disminuir la produccion de sebo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure | ||
| FA | Abandonment or withdrawal | ||
| FB | Suspension of granting procedure |